FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib
Exelixis(EXEL) ZACKS·2025-01-11 03:45Exelixis, Inc. (EXEL) announced that the FDA has notified it about an update to its supplemental new drug application (sNDA) for cabozantinib.The sNDA is seeking approval for cabozantinib for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic (epNET).In November 2024, the FDA notified the company that the sNDA for cabozantinib for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and ad ...